Five year follow-up of belzutifan for VHL disease
VHL disease is a hereditary disease that affects many organs of [...]
Belzutifan available on the NHS for patients with VHL disease
We are delighted to announce that the National Institute for [...]
SMC approves belzutifan for VHL kidney cancer in Scotland
We are delighted to announce that the Scottish Medicines Consortium [...]
FDA approves belzutifan for VHL kidney cancer
The FDA has approved a new drug called belzutifan for [...]
HIF-2α inhibitor belzutifan to be fast-tracked for approval for VHL kidney cancer
Kidney cancers frequently have mutations in a gene called the [...]
What is genetic testing for cancer?
This article gives a good summary of the use of [...]
2020 top stories in kidney cancer
This article summarises the key breakthroughs in the treatment of [...]
Treatment of kidney masses in patients with VHL disease
In this video interview, Dr Eric Jonasch from MD Anderson [...]
